Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.3014
Abstract: Importance Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. Furthermore, little is known about the factors associated with drug survival of dupilumab in AD. Objective To describe the drug… read more here.
Keywords: year; drug survival; bioday registry; dupilumab drug ... See more keywords
Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011
Sign Up to like & getrecommendations! Published in 2018 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-018-1321-4
Abstract: SummaryBackgroundRheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed… read more here.
Keywords: modifying antirheumatic; drug survival; disease modifying; biological disease ... See more keywords
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2024 at "Drugs"
DOI: 10.1007/s40265-024-02028-1
Abstract: The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival… read more here.
Keywords: drug survival; survival; survival inhibitors; registry electronic ... See more keywords
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.02.031
Abstract: To the Editor: Secukinumab, an interleukin 17A inhibitor approved for the treatment of moderate-tosevere plaque psoriasis, has shown high levels of clinical efficacy and a favorable safety profile in both short-term and long-term clinical trials.… read more here.
Keywords: drug survival; study; drug; secukinumab drug ... See more keywords
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2017.01.008
Abstract: OBJECTIVES To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS This is a non-interventional, longitudinal… read more here.
Keywords: drug survival; golimumab; drug; discontinuation ... See more keywords
Real world efficacy safety and drug survival of secukinumab over 6 years at the largest biological center in Poland
Sign Up to like & getrecommendations! Published in 2025 at "Scientific Reports"
DOI: 10.1038/s41598-025-11070-2
Abstract: Advances in biologic and targeted synthetic DMARDs have expanded treatment options for spondylarthritis. Despite improvements with TNF inhibitors, many patients remain refractory. Secukinumab, an IL-17A inhibitor, has shown promise in controlled trials. This study evaluates… read more here.
Keywords: drug survival; treatment; real world; efficacy safety ... See more keywords
Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2082354
Abstract: Abstract Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective… read more here.
Keywords: safety; secukinumab; drug survival; ixekizumab secukinumab ... See more keywords
Predisposition to conjunctivitis and male sex reduces drug survival of dupilumab in adults and adolescents
Sign Up to like & getrecommendations! Published in 2024 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2024.2372367
Abstract: ABSTRACT Background There are currently limited data on dupilumab drug survival (DS), especially on factors possibly associated with drug discontinuation. Materials and methods The primary endpoint of this study is to evaluate the parameters that… read more here.
Keywords: drug survival; conjunctivitis; drug; male ... See more keywords
Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
Sign Up to like & getrecommendations! Published in 2021 at "Expert review of clinical pharmacology"
DOI: 10.1080/17512433.2021.1979394
Abstract: BACKGROUND The demand of biologic switching is increasing for different reasons. We aimed to define reasons for switching biologics and possible predictors for switching risk, and to estimate data on drug survival. METHODS One-hundred and… read more here.
Keywords: psoriatic arthritis; line; drug survival; drug ... See more keywords
Drug survival, effectiveness, and safety of risankizumab for moderate-to-severe psoriasis for up to 4 years.
Sign Up to like & getrecommendations! Published in 2025 at "Clinical and experimental dermatology"
DOI: 10.1093/ced/llaf305
Abstract: BACKGROUND Risankizumab has been shown to be safe and effective for the treatment of psoriasis in numerous randomized clinical trials and real-life studies. Real-life data on treatment for up to 4 years are lacking. OBJECTIVES… read more here.
Keywords: safety; safety risankizumab; drug survival; effectiveness ... See more keywords
P548 Drug Survival in Patients with Inflammatory Bowel disease: An observational study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.669
Abstract: Although the therapeutic array has significantly widened, over the past decades predicting treatment persistence in IBD patients is still a challenge. In this study we collected longitudinal data to determine drug survival on the medications… read more here.
Keywords: patients still; study; year; drug survival ... See more keywords